PD-1 Resistant Head and Neck Cancer Market: How Are Next-Generation Immunotherapy Combinations Reshaping the Post-Checkpoint Landscape?
PD-1 resistance in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) — the clinical challenge where approximately 80% of patients fail to achieve durable responses to first-line immunotherapy, creating the most urgent unmet need in the PD-1 Resistant Head and Neck Cancer Market — represents the fastest-emerging therapeutic frontier, with next-generation...
0 Commenti
0 condivisioni
15 Views